Erstlinientherapie beim metastasierten hormonsensitiven Prostatakarzinom (mHSPC)First-line treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
H. Rexer
S. Feyerabend
M. Graefen
机构：
[1] AUO Geschäftsstelle,
[2] Studienpraxis Nürtingen,undefined
[3] Organgruppe Prostatakarzinom der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V.,undefined
来源：
Forum | 2023年 / 38卷 / 3期
关键词：
D O I：
10.1007/s12312-023-01201-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：238 / 239
页数：1
相关论文
共 50 条
  • [21] SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
    Omrcen, Tomislav
    ACTA CLINICA CROATICA, 2022, 61 : 81 - 85
  • [22] Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).
    Albiges, Laurence
    Xie, Wanling
    Chen, Yu-Hui
    Boher, Jean-Marie
    Valenca, Loana Bueno
    Bernard, Brandon David
    Culine, Stephane
    Habibian, Muriel
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Liu, Glenn
    Pomerantz, Mark
    Nakabayashi, Mari
    Kantoff, Philip W.
    Fizazi, Karim
    Gravis, Gwenaelle
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC).
    Friedland, David
    Barry, Amanda
    Ellis, Peter G.
    Sweeney, Christopher
    McCutcheon, Stephanie
    Lokay, Kathleen
    Benson, Hans
    Krebs, Melinda
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2023, 25 (01) : 1 - 4
  • [25] Genomic profiles and clinical outcomes to distinguish primary from secondary metastatic hormone-sensitive prostate cancer (mHSPC).
    Nizialek, Emily
    Lim, Su Jin
    Wang, Hao
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)
    Henriquez, Ivan
    Malave, Barbara
    Campos, Fernando Lopez
    Hidalgo, Elena Centelles
    Muelas, Rodrigo
    Ferrer, Carlos
    Munoz-Rodriguez, Jesus
    Villamon, Agustina Mendez
    Pascual, Maria Cerrolaza
    Badia, Joan
    Fuertes, Jordi
    Hinojosa-Salas, Percy
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (02): : 706 - 715
  • [27] Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
    Garcia De Herreros, M.
    Jimenez Blasco, N.
    Reig Torras, O.
    Ferrer Mileo, L.
    Aversa, C.
    Garcia-Esteve, S.
    Rodriguez-Carunchio, L.
    Trias Puigsureda, I.
    Padrosa, J.
    Fernandez Manas, L.
    Marin, M.
    Font Pous, A.
    Rodriguez-Vida, A.
    Climent Duran, M. A.
    Cros Costa, S.
    Chirivella Gonzalez, I.
    Figols Gorina, M.
    Mellado Gonzalez, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S992 - S992
  • [28] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [29] Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC).
    Alex, Anitha
    Stenehjem, David D.
    Twardowski, Przemyslaw
    Cheng, Heather H.
    Gill, David Michael
    Buckley, Tyler Howard
    Patel, Shiven B.
    Kessler, Elizabeth Riley
    Chittoria, Namita
    Poudel, Aarati
    Vaishampayan, Ulka N.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345